Work at Dark Blue Therapeutics Ltd. has led to the identification of proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a MLLT1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results